What is Amfexa (dexamfetamine sulfate) licensed to treat in children and adolescents aged 6 to 17 years?

Amfexa (dexamfetamine sulfate) is licensed to treat attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6–17 years as part of a comprehensive treatment programme when previous methylphenidate treatment has produced a clinically inadequate response, under specialist supervision.